, /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced additions to its leadership team through key executive appointments and promotions. Today's personnel announcement accompanies Flagship's expansion of its capital base with a capital pool of to support the origination and growth of an estimated 25 breakthrough platform companies in human health, sustainability, and AI. , Ph.
D., has been promoted to General Partner. Afzelius joined Flagship in 2020 after leading Pfizer's systems immunology function, where she served as executive director of clinical programs.
A computational scientist by training, Afzelius came to Flagship with twenty years of leadership experience. Afzelius' past roles included CEO, co-founder, president, chairperson of the board, and executive director in both emerging biotech and large pharma companies. "Lovisa has showcased her exemplary leadership, vision, and commitment to pioneering original science, as evidenced by her instrumental role in the creation and scaling-up of Alltrna, Apriori Bio, Metaphore Biotechnologies, and Prologue Medicines," said , Ph.
D., Founder and CEO of Flagship Pioneering. "I am pleased with the promotion of Lovisa to General Partner, and look forward to her continued dedication to our mission.
" has also been promoted to General Partner. Biondi joined Flagship in 2019 following nearly two decades at Bristol-Myers Squibb (BMS), where he most recently served as Senior Vice President of Strate.